Boehringer Ingelheim’s Phase II Alzheimer’s disease trials with investigational compound BI 409306 has not met their efficacy endpoints.    Because of this, plans for further trials with BI 409306 in AD will not be pursued. Instead, the company will refocus efforts on the ongoing schizophrenia trials with this compound.   These AD trials were part of an extensive clinical trial program exploring the efficacy of compounds which target malfunctioning of specific (glutamatergi...